John ForbesAustralian‐New Zealand Breast Cancer Trials Group Operations Office, Hunter Oncology CentreThe University of NewcastleNewcastle Mater Misericordiae HospitalWaratahNSW2298John Wiley & Sons, LtdMedical Journal of Australia
We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Patients received 1 year/18
The initial trial is for up to 50 patients in hospitals in Belfast, Glasgow, Newcastle, and the Royal Marsden in London that are within the UK Experimental Cancer Medicine Centre (ECMC) network. Read more:Investigational therapy for advanced cancers enters trials The role of ‘cheating’ cancer ...
The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. This was a national cohort study of patients with ear
chromogenic in situ hybridization (CISH) using the HER-2 DNA probe generated by SPT HER-2 DNA probe (Zymed) was first reported to evaluate against FISH (PathVision, Vysis, Downers Grove, IL) and a HER-2 antibody CB11 (Novocastra, Newcastle, UK) in 157 breast cancer tissue specimens (Tan...
Forbes, ANZ Breast Cancer Trials Group, University of Newcastle, Locked Bag 7, Hunter Region Mail Centre, NSW 2310, Newcastle, Australia (Absent); Richard D. Gelber, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA; ...
R Plummer Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK Breast Cancer Research 2011, 13(Suppl 2):O3 (doi: 10.1186/bcr3002) Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-binding enzyme activated by DNA strand breaks and has a key role in ...
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic featu
5Pathology North, John Hunter Hospital, Newcastle, NSW, 2305, Australia. 6Department of Surgical Oncology, Calvary Mater Newcastle Hospital, Australian New Zealand Breast Cancer Trials Group, and School of Medicine and Public Health, University of Newcastle, NSW, 2308, Australia. *These authors ...
Independent Data Monitoring Committee: H Lucraft (Chair, Newcastle General Hospital), M Parmar (MRC Clinical Trials Unit, London), I Turesson (Akadamiska Sjukhuset, Uppsala, Sweden). Consumers (observers to Trial Management Group): M Carling (RAGE), J Pritchard (independent), M King (ex-mem...